Showing 15 posts of 20 posts found.

Sanofi image

Sanofi sees FDA approval for diabetes drug

February 26, 2015
Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

Sanofi image

Sanofi sales lifted by diabetes and rare diseases

February 6, 2015
Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

AZ image

AstraZeneca looks for revenue boost via Actavis buy

February 6, 2015
Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

GSK image

GSK blames respiratory woes as sales drop

February 5, 2015
Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales

GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …

Gilead image

Gilead sales soar on back of hepatitis drugs

February 4, 2015
Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi

The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …

Roche image

Roche oncology sales shine but profits dip

January 29, 2015
Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4

Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …

Novartis image

Novartis sales below forecast in ‘transformative’ year

January 28, 2015
Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan

Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …

Pfizer image

Pfizer posts fourth-quarter revenue decline

January 28, 2015
Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate

Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …

Xarelto image

NICE recommends Bayer heart attack drug

January 26, 2015
Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban

NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …

J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

Merck image

Merck: ‘2014 revenues will be down’

February 7, 2014
Sales and Marketing Frazier, Merck, Simponi, Singulair, isentress, q4, results

Merck is the latest pharma company to release figures suggesting 2013 was more of a struggle than it would like, …

Astrazeneca image

AstraZeneca battling ‘headwinds’

February 7, 2014
Sales and Marketing AstraZeneca, Soriot, farxiga, q4, results, xigduo

AstraZeneca is to shed another 550 jobs as its latest corporate restructure takes shape, bringing to 5,600 the number of …

Sanofi’s chief executive Christopher Viehbacher image

Analysts ‘disappointed’ by Sanofi guidance

February 6, 2014
Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales

Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …

gsk image

GSK to make ‘fundamental changes’

February 6, 2014
Sales and Marketing China, GSK, Tafinlar, Witty, q4, results

GlaxoSmithKline has pledged to make ‘fundamental changes’ to the manner in which it does business, looking at its interaction with …

Lilly image

Lilly to go ‘on offense’

January 31, 2014
Sales and Marketing Alimta, Lechleiter, cymbalta, lilly, q4, zyprexa

The loss of patent on antidepressant Cymbalta in the US last December was largely responsible for Eli Lilly & Co’s …

Latest content